VCAM1 and fibrosis: These pilot data support that VCAM-1 molecular imaging could be a first-in-class tool to identify amongst subjects with apparently benign liver disease (i.e., no or mild fibrosis), those with severe liver inflammation—hence the most at-risk for progression.